Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan (APL-2) in Eculizumab-Naive PNH Patients
NCT03593200Phase 2Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- Oct 2019
- Modality
- PEGylated Peptides
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Apellis Pharmaceuticals. Primary endpoints: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity, Mean Change From Baseline in Lactate Dehydrogenase (LDH) Level at Day 365 and 2 more. Started Aug 2018; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT03593200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03593200.